Propanc Biopharma, Inc. (PPCB) stock
PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$1.94+0.02 (+1.09%)
Close on Nov 13, 2026Market cap $12.29MP/E –Yield –
Propanc Biopharma cash
Cash and short-term investments held at the end of each period.
Propanc Biopharma's cash was $258.37K at Sep 30, 2026. For fiscal 2026 it was $832.01K, up 6782.9% from the year before. Over ten years it grew 21.3% a year on average. The highest annual figure on record is $832.01K in fiscal 2026.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $832.01K | +6782.9% |
| FY2025 | Jun 30, 2025 | $12.09K | -42.7% |
| FY2024 | Jun 30, 2024 | $21.09K | +109.9% |
| FY2023 | Jun 30, 2023 | $10.05K | +147.0% |
| FY2022 | Jun 30, 2022 | $4.07K | +80.4% |
| FY2021 | Jun 30, 2021 | $2.26K | -96.6% |
| FY2020 | Jun 30, 2020 | $67.01K | +2699.0% |
| FY2019 | Jun 30, 2019 | $2.39K | -88.0% |
| FY2018 | Jun 30, 2018 | $19.92K | -71.1% |
| FY2017 | Jun 30, 2017 | $69.04K | -43.0% |
| FY2016 | Jun 30, 2016 | $121.07K | +12.5% |
| FY2015 | Jun 30, 2015 | $107.63K | +22.6% |
| FY2014 | Jun 30, 2014 | $87.80K | – |
| FY2013 | Jun 30, 2013 | $0 | -100.0% |
| FY2012 | Jun 30, 2012 | $179 | +35.6% |
| FY2011 | Jun 30, 2011 | $132 | -75.0% |
| FY2010 | Jun 30, 2010 | $528 | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $258.37K | -57.1% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $832.01K | +6782.9% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $443.70K | +774.1% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $561.24K | +3735.4% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $602.74K | +6403.4% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $12.09K | -42.7% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $50.76K | +715.8% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $14.63K | -79.6% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $9.27K | +39.9% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $21.09K | +109.9% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $6.22K | -93.3% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $71.65K | +192.7% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $6.63K | -65.8% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $10.05K | +147.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $93.24K | -30.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $24.48K | -66.8% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $19.40K | -57.7% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $4.07K | +80.4% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $133.89K | +827.2% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $73.62K | +246.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $45.82K | -10.5% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $2.26K | -96.6% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $14.44K | -46.4% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $21.24K | +76.7% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $51.22K | -46.7% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $67.01K | +2699.0% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $26.96K | -74.9% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $12.02K | -90.3% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $96.12K | +147.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $2.39K | -88.0% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $107.21K | +1053.3% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $124.54K | +10.7% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $38.91K | -72.7% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $19.92K | -71.1% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $9.30K | +2.6% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $112.50K | +162.1% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $142.57K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $69.04K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $9.06K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $42.92K | – |
See a number that looks wrong?